Escin in Patients With Covid-19 Infection

• Status: Recruiting
• Trial end date: 2020-12-30
• Target enrollment: 0
• Participant gender: All

Summary

In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000 people were infected and over 2000 people died all over the world. There is no specific drug treatment for this disease. Considering that lung damage is related to both viral infection and burst of cytokines, our idea is to evaluate the efficacy and safety of escin as add-on treatment to conventional antiviral drugs in COVID-19 infected patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Catanzaro
• Collaborators: Azienda Ospedaliera Pugliese Ciaccio; Azienda Ospedaliera Universitaria Mater Domini, Catanzaro

Criteria

Inclusion Criteria:

• Aged between 18 and 75 years, extremes included, male or female

• Positivity to covid-19 screening test in molecular biology

• In escin group: Low response to standard treatment

• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Female subjects who are pregnant or breastfeeding.

• patients with previous history to allergy

• patients meet the contraindications of escin

• Patients have any condition that in the judgement of the Investigators would make the subject inappropriate for entry into this study.

• patients can't take drugs orally